Research shows that green tea extract reduces low-density lipoproteins (LDL) in overweight and obese women after six weeks of treatment
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for glycemic control, have emerged as modulators of vascular biology with potential anti-atherosclerotic effects
Taken together, evidence suggests that the ENS may mediate gutbrain signaling that regulates metabolic homeostasis
Various A-listers like Khloe Kardashian have denied taking GLP-1 or its competitors to get in shape, while others such as Chelsea Handler, Elon Musk, and Sharon Osbourne have spoken out about their experiences
States with no obesity GLP-1 coverage: Most remaining states including Texas, Florida, Ohio, New Jersey, and Georgia do not cover GLP-1s for obesity at all
Insurance coverage patterns vary significantly between medications